Conflict of interest statement: W. Munakata has received grants from Ono 
Pharmaceutical Co., Ltd. K. Ando has received grants from Ono Pharmaceutical 
Co., Ltd. K. Hatake has received grants from Ono Pharmaceutical Co., Ltd. and 
Chugai Pharmaceutical Co., Ltd. N. Fukuhara has received grants from Ono 
Pharmaceutical Co., Ltd. T. Kinoshita has received grants and/or personal fees 
from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Solasia 
Pharma K.K., Ono Pharmaceutical Co., Ltd., Gilead Sciences, Inc., MSD, Zenyaku 
Kogyo, Bristol‐Myers Squibb, Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., and 
Janssen Pharmaceutica. S. Fukuhara has received grants from Ono Pharmaceutical 
Co., Ltd. Y. Shirasugi has received personal fees from Novartis. M. Yokoyama has 
received grants from Ono Pharmaceutical Co., Ltd. and personal fees from Chugai 
Pharmaceutical Co., Ltd. S. Ichikawa has received grants from Ono Pharmaceutical 
Co., Ltd. K. Ohmachi has received grants from Ono Pharmaceutical Co., Ltd. and 
personal fees from Ono Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., 
Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Takeda 
Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. N. Gion is an 
employee of Ono Pharmaceutical Co., Ltd., and has received personal fees. A. Aoi 
is an employee of Ono Pharmaceutical Co., Ltd., and has received personal fees. 
K. Tobinai has received grants and/or personal fees from Ono Pharmaceutical Co., 
Ltd., Celgene, Zenyaku Kogyo, HUYA Bioscience International LLC, Eisai Co., 
Ltd., Takeda Pharmaceutical Co., Ltd., Mundipharma, Janssen Pharmaceutical, 
Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., GlaxoSmithKline, 
and AbbVie Inc.